Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Buy” by Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has earned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $12.75.

A number of equities analysts have commented on CATX shares. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Truist Financial decreased their price target on shares of Perspective Therapeutics from $21.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday, March 31st. Finally, Royal Bank of Canada lowered their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, March 27th.

Perspective Therapeutics Trading Down 5.1 %

Shares of NYSE CATX opened at $2.43 on Tuesday. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $19.05. The stock has a 50 day moving average of $2.27 and a 200-day moving average of $4.19.

Insider Buying and Selling

In other news, CEO Johan M. Spoor acquired 22,026 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The shares were purchased at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at approximately $133,017.92. This represents a 58.96 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert F. Williamson III bought 38,145 shares of the company’s stock in a transaction dated Monday, March 31st. The stock was purchased at an average price of $2.14 per share, with a total value of $81,630.30. Following the completion of the transaction, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This represents a 53.85 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 115,696 shares of company stock valued at $256,344 over the last 90 days. 3.52% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

A number of large investors have recently modified their holdings of CATX. Millennium Management LLC bought a new stake in shares of Perspective Therapeutics during the 4th quarter worth $4,132,000. Octagon Capital Advisors LP raised its stake in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after acquiring an additional 882,528 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after acquiring an additional 800,000 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $2,075,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Perspective Therapeutics during the 4th quarter valued at approximately $1,595,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.